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Imatinib has become the standard primary approach for the
treatment of a newly diagnosed chronic phase myeloid leukemia
(CML) patient, recently. Complete cytogenetic response is
achieved on the majority of patients under treatment, but the
disease remains in molecular level and after discontinuation of the
drug, relapses occur inevitably. In imatinib era centers are referring
only the patients, who has imatinib resistance or patients with high
relapse risk. Secondly, the period from diagnosis to transplantation
is an important nominator. In imatinib era CML patients will ﬁrst
undergo a trial of imatinib and according to the response they will
be referred to the allogeneic transplant program. There is lack of
data about the impact of delayed referral and emerging imatinib
resistance on allogeneic transplant outcome. We have performed a
case-matched control analysis in our CML (n: 173). CML patients
who received imatinib before transplantation (n20), were
matched according EBMT (Gratwohl) score with imatinib naive
ones (n40). The median age at transplant in the imatinib group
was 39 (19-57), gender F/M: 10/10, disease status 1st CP:13, 2nd
CP: 4, AP: 2, BP: 1. The median total imatinib dose that was used
until transplantation was 93gr (33-648), and imatinib therapy was
discontinued at a median of 17, 5 (7-210) days prior to the trans-
plantation. Only one of 20 patients was in molecular remission
before transplantation. according to the EBMT score. The median
age of 40 patients in imatinib naı¨ve group was 34 years (14-53),
gender F/M: 14/26, and disease status 1st CP:32, 2nd CP:2, AP: 3,
BP: 3. The two groups were similar according to their age, sex,
conditioning regimen, stem cell sources and Grathwohl scores.
Engraftment for neutrophil 0,5109/L, and platelet 
20109/L was median 15 (13-20) days and 13 (10-32) days in the
imatinib group while it is 16 (0-28) days and 15 (0-36) days in the
imatinib naive group. The response to transplantation, transplan-
tation related mortality, the incidence of acute and chronic
GVHDH for each group were not signiﬁcantly different. More-
over, no signiﬁcant difference was determined between 2-year’s
disease free survival and overall survival rates (Table). Our single
center analysis is in concordance with several recent reports. In this
study, it is observed that imatinib use prior to AHSCT does not
negatively affect the early transplant related outcome.
STI () n: 20 STI (-) n: 40 p
Median age 39 (18-57) 34 (14-53) 0,160
Grathwohl score
(1,2,3,4) 1/2/7/6/4 1/6/20/10/3 0,545
Time Diagnosis-
Transplant (month) 16,9 (5,4-75,8) 11,6 (4,2-129,3) 0,076
Stem cell source (PB/
BM) 15/5 30/10
Conditioning regimen
(Ablative/RIC) 10/10 28/12 0,161
Sex (Female/Male) 10/10 14/26 0,751
Engraftment 19/20 39/40 0,559
NEU>0.510e9/L 15 (13-20) 16 (0-28) 0,639
Transplantation-
related mortality 3/20 6/40 1
Acute GvHD (II-IV) 3/19 17/40 0,076
Chronic GvHD 8/16 22/34 0,322
Relapse rate 3/20 14/40 0,136
2-year’s disease free
survival % 55,4%13,2 % 46,7%7,9 0,595
2-year’s overall
survival %71,513,4 % 59,4%7,9 0,463
PB: Peripheral blood, BM: Bone morrow, RIC: Reduced intensity
conditioning
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HUMAN HERPESVIRUS-6 ENCEPHALITIS FOLLOWING ALLOGENEIC HE-
MATOPOIETIC STEM CELL TRANSPLANTATION
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Approximately 50% recipients of allo-HSCT develop human
herpes virus-6 (HHV-6) viremia detectable by polymerase chain
reaction ampliﬁcation (HHV-6 PCR), but the clinical signiﬁcance
of this asymptomatic viremia is unclear. Five of 53(9.4%) patients
who received Alemtuzumab (total dose, 40 mg) supported condi-
tioning (CY-TBI 3, BU-TBI1, Flu-Mel1, MUD 3,
MMUD 1, MMRD1) and Tacrolimus as GVHD prophylaxis
subsequently developed HHV-6 encephalitis whilst receiving an-
tiviral prophylaxis (Valciclovir 4 and Valganciclovir 1). Acute
GVHD (grade II 1, grade III2, grade IV2) preceded enceph-
alitis and had necessitated, prednisone 5, Inﬂiximab 1, Alemtu-
zumab 1, and Daclizumab 1. HSV-6 encephalitis became ap-
parrent at 41-103 days (median 60 days) presenting with confusion
(n5), amnesia (n 3) and seizures (n2). MRI revealed non-
speciﬁc white matter changes in 4 and a non enhancing medial
temporal lobe lesion in one of the patients. CSF protein was
elevated in 4 patients (table-1); CSF-pleocytosis was mild with a
median of 3- lymphocytes/hpf. HSV-6 PCR on blood (plasma)
revealed 100-22,500 (median 1200) DNA copies/ml. CSF PCR
was positive in all 5 patients at 600-225,000 (median 4700) copies/
ml). CSF HHV6 was several fold higher than plasma levels (table-
1). EEG was nonspeciﬁc in all 5 patients. Intravenous administra-
tion of foscarnet resulted in neurological improvement at 8-13
(median 11) days and negative plasma PCR at 30-66 (median 50)
days; recovery of short-term memory loss was more prolonged. In
the patient with negative plasma PCR, CSF PCR became negative
on 50th day of therapy. Four patients had complete neurological
recovery; one patient (#2) had transient improvement before suc-
cumbing to multi-organ failure. We conclude that, HSV-6 en-
cephalitis complicates approximately 10% of in vivo T cell depleted
allo-HSCT. Poor yield of routine CSF, MRI and EEG examina-
tion calls for high index of suspicion and CSF examination for
HHV-6 PCR. Prompt antiviral treatment with foscarnet appears
effective.
Table-1: HSV-6 Encephalitis following allo-HSCT
Age/
Sex
Onset/
Day Manifestation
HSV-6
CSF
(copy/ml)
HSV-6
Blood
(copy/ml) Outcome
Other
viral
infections
Follow-up
Months
46F 41 Amnesia,
confusion,
seizure
4700 Negative Complete
resolution
Herpes
zoster
Alive 12
months
66F 103 Confusion,
somnolence,
disorganized
speech
225,000 22,500 Transient
improvement
CMV Died day
147
41M 60 Amnesia,
confusion
Positive* 200 Complete
resolution
None Alive 36
months
39M 35 Amnesia,
confusion,
tremor
4800 100 Complete BK virus
resolution
Alive 6
months
58F 83 Seizure,
confusion
600 2700 Complete
resolution
None Died day
120
Abbreviations: M- male, F- female, allo-HSCT- allogeneic hema-
topoietic stem cell transplant, MRI- Magnetic resonance im-
aging, HHV- Human herpes virus, Prot- Protein, Leu- Leu-
kocytes, CSF- Cerebrospinal ﬂuid, WM- white mater, *
Quantitative PCR not available
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CD154:CD40 CO-STIMULATORY BLOCKADE AT PRIMARY BMT PRO-
MOTES ALLOGENEIC ENGRAFTMENT IN SECONDARY BMT BY BLOCK-
ING SENSITIZATION
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